ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA

This research demonstrated treatment results of 45 patients with chronic myeloid leukemia who were monitored from 2006 to 2015 year. The article is aimed to evaluate a frequency of achievement of hematologic, cytogenetic, molecular responses in patients administered with tyrosine kinase inhibitors, prevalence of resistance to imatinib and its toxicity. It is shown that the treatment of choice for CML is tyrosine kinase inhibitor - imatinib. The use of tyrosine kinase inhibitors allows to reach deep cytogenetic and molecular remission in patients with chronic myeloid leukemia which leads to increased survival. Authors have noted a high prevalence of primary and secondary resistance to first generation tyrosine kinase inhibitor - imatinib. Investigation of results demonstrated that regular hematological, cytogenetic and molecular monitoring is required for effective disease control.